Net sales were 2.425 billion yen (up 11.9% YoY), operating loss was 136 million yen, and quarterly net income was 6 million yen. Due to drug price revision, gross profit declined. Conversely, gains on sales of marketable securities were recorded, leading to a YoY increase in quarterly net income. The full-year forecast remains unchanged from the previous forecast. The segments encompass Pharmaceuticals, Healthcare, Global, and Real Estate Leasing. The equity ratio improved to 73.9%. <\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4512","jir_company_name":"Wakame Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4512-20260805-01.pdf","jir_short_summary":"Net sales were 2.425 billion yen (up 11.9% YoY), operating loss was 136 million yen, and quarterly net income was 6 million yen. Due to drug price revision, gross profit declined. Conversely, gains on sales of marketable securities were recorded, leading to a YoY increase in quarterly net income. The full-year forecast remains unchanged from the previous forecast. The segments encompass Pharmaceuticals, Healthcare, Global, and Real Estate Leasing. The equity ratio improved to 73.9%. ","jir_summary":"### Performance overview\nIn the first quarter of the fiscal year ending March 2027, net sales reached 2,425,000,000 yen due to growth in domestic and international sales of the brand products and increased contract manufacturing of ophthalmic solutions. However, gross profit declined due to drug price revisions. Operating loss was 136 million yen, ordinary loss was 170 million yen, but quarterly net income turned positive at 6 million yen owing to gains on the sale of marketable securities.\n\n### Segmental overview and financial position\nPharmaceuticals sales increased; Healthcare remained solid; Global grew through contract manufacturing and cross-border e-commerce expansion. Real estate leasing showed steady growth. Total assets stood at 15,857 million yen, equity ratio at 73.9%, net assets at 11,718 million yen. The earnings forecast for the period remains unchanged from the prior announcement.","jir_financial_highlights":"Net sales: 24,25,000,000\u5186 (YoY +11.9%)\nOperating loss: 1,360,000,000\u5186 (YoY +6 hundred\u4e07\u5186)\nOrdinary loss: 1,700,000,000\u5186 (YoY +1,000,000\u5186)\nQuarterly net income: 6,000,000\u5186 (YoY increase)\nEquity ratio: 73.9\uff05 (Improved by 1.1 percentage points YoY)","jir_category":"","jir_hashtags":"#WakamoToPharmaceutical, #financial_summary, #JapanEquities","jir_key_figures":"Net sales: 24,25, BTC 2 50,000,000? (unclear) \nFull-year net sales forecast: 11,000 million yen (full-year)\nFull-year net income: 230 million yen (full-year)","jir_meta_title":"Wakamo Pharmaceutical Co., Ltd. | First Quarter Financial Summary for FY2019? March 2027: Revenue Increase but Profit Pressure; Full-Year Forecast Unchanged","jir_meta_description":"Overview of Wakamo Pharmaceutical's Q1 FY2027 financial results. Net sales increased 11.9% YoY; operating and ordinary losses widened, but quarterly net income turned positive due to gains on sale of marketable securities. Full-year forecast unchanged. Summary of segment performance and financial position.","jir_og_title":"Wakamo Pharmaceutical's Q1 Results: Revenue Up, Profit Faces Pressure","jir_og_description":"Q1 FY2027 results for Wakamo Pharmaceutical. Revenue up YoY, operating and ordinary losses, but quarterly net income turned positive. Full-year forecast unchanged. An explanation of segment trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58985,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-95482","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n